ClinicalTrials.gg
CompletedNCT04093453PROEMUpdated Aug 23, 2024Results posted

The Acute Effect of Propionate on Energy Homeostasis

An interventional study of Placebo (Sodium Chloride) and Exercise in Obesity, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Imperial College London · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Feb 2018, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Obesity by Imperial College London — 5 open to participants now, 6 under way, none of them phase 3. Obesity · Imperial College London.

Enrollment
14th of 27
53 · median 53
Started
2018
with 3 others
No phase
21 of 36
4 open now
Registered
30th of 36
by date

Among the 36 studies in Obesity by Imperial College London, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2018, is one of 21 with no phase, and was the 30th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 36 studies in Obesity by Imperial College London are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Obesity by Imperial College London, or all of them as a file.
02

Study summary

The research project aims to examine the effect of a dietary supplement called propionate on how the human body in healthy adults aged (18- 65 years) responds to during fasting, exercise and following a liquid mixed meal test and how that would affect energy homeostasis and substrate oxidation.

Read the detailed description

Dietary fibres have long been recognised for their important role in a healthy diet due to their negative association with, and even management of, chronic diseases such as obesity, diabetes, metabolic syndrome, cardiovascular disease and inflammatory-bowel disease among others.Emerging evidence has suggested that these benefits could largely be attributed to short chain fatty acids (SCFA) (acetate, propionate and butyrate), the main by-products of fibre fermentation in the gut. Previous research has demonstrated that a long-term elevation in the SCFA propionate significantly reduced body weight gain in overweight adults and reduced liver fat storage.

The current project will examine potential mechanisms for the positive effect of propionate on energy homeostasis and metabolic profile.The effects of propionate on circulating glucose, insulin, gut hormones and lipid levels at rest, following moderate-intensity exercise and mixed meal tolerance test will be examined.

To acutely increase propionate absorption from the gut the present project will use a simple nutritional supplement: sodium propionate in a hydroxypropylmethyl cellulose (HPMC) capsule. This capsule is coated with an enteric film which prevents gastric digestion until the capsule reaches the intestine. This nutritional supplement has been used in human volunteers in a previously approved ethics application (12/LO/1769: Oral propionate and glucose homeostasis). A 5g acute dose of sodium propionate had previously been tested and reported no adverse effects . The MHRA have confirmed that encapsulated sodium propionate is not classed as an investigative medicinal product.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Short Chain Fatty Acids
  • Propionate
  • Energy Expenditure
  • Lipid Oxidation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers ( (BMI) of 18-35 kg/m2)
  • Age between 18-65 years (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Weight change of ≥ 3kg in the preceding 2 months
  • Current smokers
  • Substance abuse
  • Excess alcohol intake
  • Pregnancy
  • Diabetes
  • Cardiovascular disease
  • Cancer
  • Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome
  • Kidney disease
  • Liver disease
  • Pancreatitis
  • Started new medication within the last 3 months likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or , antibiotics, androgens, phenytoin, erythromycin or thyroid hormones.
  • Involved in current research or have recently been involved in any research prior to recruitment in the past 12 weeks.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Placebo comparator
    Placebo + Fasting

    Sodium Chloride tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).

    Other: Placebo (Sodium Chloride)

  • Placebo comparator
    Placebo + Exercise

    Sodium Chloride tested in an exercise state. Participants will have the placebo then exercise will be performed at 40% of maximal aerobic capacity for one hour.

    Other: Placebo (Sodium Chloride) · Other: Exercise

  • Placebo comparator
    Placebo + Post-prandial

    Sodium Chloride tested in a post-prandial state. Participants will have the placebo then a mixed liquid meal test is given.

    Other: Placebo (Sodium Chloride)

  • Experimental
    Propionate and Fasting

    Sodium Propionate tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).

    Dietary Supplement: Sodium Propionate

  • Experimental
    Propionate and Exercise

    Sodium Propionate tested in an exercise state. Participants will have the sodium propionate then exercise will be performed at 40% of maximal aerobic capacity for one hour.

    Other: Exercise · Dietary Supplement: Sodium Propionate

  • Experimental
    Propionate and Post-prandial

    Sodium Propionate tested in a post-prandial state. Participants will have the sodium propionate then a mixed liquid meal test is given.

    Dietary Supplement: Sodium Propionate

Interventions

  • OtherPlacebo (Sodium Chloride)

    Participant receive Placebo (Sodium Chloride)

  • OtherExercise

    1 hour exercise

  • Dietary supplementSodium Propionate

    Participant receive Sodium Propionate

06

What researchers measure

Primary outcomes

  1. Changes in Resting Energy Expenditure

    Changes in Resting Energy Expenditure between sodium propionate and sodium chloride (control).

    Time frame: 6 hours

  2. Changes in Resting Lipid Oxidation

    Changes in Resting Lipid Oxidation between sodium propionate and sodium chloride (control).

    Time frame: 6 hours

  3. Changes in Energy Expenditure During Exercise

    Changes in Energy Expenditure between sodium propionate and sodium chloride (control) during exercise.

    Time frame: 240 minutes

  4. Changes in Lipid Oxidation During Exercise

    Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) during exercise.

    Time frame: 240 minutes

  5. Changes in Energy Expenditure Post-prandially

    Changes in Energy Expenditure between sodium propionate and sodium chloride (control) post-prandially.

    Time frame: 300 minutes

  6. Changes in Lipid Oxidation Post-prandially

    Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) post-prandially.

    Time frame: 300 minutes

  7. Changes in Glucose Concentrations Post-prandially

    Changes in glucose concentrations between sodium propionate and sodium chloride (control) post-prandially.

    Time frame: 300 minutes

  8. Changes in Glucose Concentrations During Exercise

    Changes in glucose concentrations between sodium propionate and sodium chloride (control) during exercise.

    Time frame: 240 minutes

  9. Changes in Subjective Thirst Post-prandially Using a Visual Analog Scale (100 mm).

    Changes in subjective thirst between sodium propionate and sodium chloride (control) post-prandially. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.

    Time frame: 300 minutes

  10. Changes in Subjective Thirst During Exercise With Visual Analog Scales (100 mm)

    Changes in subjective thirst between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.

    Time frame: 240 minutes

  11. Changes in Subjective Nausea During Exercise With Visual Analog Scales (100 mm)

    Changes in subjective nausea between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective nausea. High (100 mm) mean high subjective nausea.

    Time frame: 240 minutes

  12. Changes in Subjective Hunger During Exercise With Visual Analog Scales (100 mm)

    Changes in subjective hunger between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.

    Time frame: 240 minutes

Secondary outcomes

  1. Changes in GLP-1 Concentration

    Changes in GLP-1 concentrations between sodium propionate and sodium chloride (control) post-prandially.

    Time frame: 300 minutes

  2. Changes in Insulin Concentration

    Changes in insulin concentrations between sodium propionate and sodium chloride (control) during fasting

    Time frame: 360 minutes

  3. Changes in Glucose Concentration

    Changes in glucose concentrations between sodium propionate and sodium chloride (control) during fasting

    Time frame: 360 minutes

  4. Changes in Free Fatty Acid Concentration

    Changes in free fatty acid concentrations between sodium propionate and sodium chloride (control) during fasting

    Time frame: 360 minutes

  5. Changes in Subjective Nausea With Visual Analog Scales (100 mm)

    Changes in subjective nausea between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective nausea. High (100 mm) mean high subjective nausea.

    Time frame: 360 minutes

  6. Changes in Subjective Hunger With Visual Analog Scales (100 mm)

    Changes in subjective hunger between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.

    Time frame: 360 minutes

  7. Changes in Subjective Thirst Using Visual Analog Scales (100 mm)

    Changes in subjective thirst between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.

    Time frame: 360 minutes

  8. Changes in Insulin Concentration

    Changes in insulin concentrations between sodium propionate and sodium chloride (control) during exercise

    Time frame: 240 minutes

  9. Changes in Insulin Concentration

    Changes in insulin concentrations between sodium propionate and sodium chloride (control) post-prandially.

    Time frame: 300 minutes

  10. Changes in Subjective Nausea Between Sodium Propionate and Sodium Chloride Post-prandially

    Changes in subjective nausea between sodium propionate and sodium chloride (control) post-prandially.

    Time frame: 300 minutes

  11. Changes in Subjective Hunger Between Sodium Propionate and Sodium Chloride Post-prandially With Visual Analog Scales (100 mm)

    Changes in subjective hunger between sodium propionate and sodium chloride (control) post-prandially. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.

    Time frame: 300 minutes

07

Results

Posted Aug 23, 2024

Participant flow

Fasted Study
Participant flow — Fasted Study
MilestoneFasted Study: Placebo/PropionateFasted Study: Propionate/PlaceboPost-Prandial Study: Placebo/PropionatePost-Prandial Study: Propionate/PlaceboExercise Study: Placebo/PropionateExercise Study: Propionate/Placebo
Started12130000
Completed1090000
Not completed240000
Postprandial Study
Participant flow — Postprandial Study
MilestoneFasted Study: Placebo/PropionateFasted Study: Propionate/PlaceboPost-Prandial Study: Placebo/PropionatePost-Prandial Study: Propionate/PlaceboExercise Study: Placebo/PropionateExercise Study: Propionate/Placebo
Started00121300
Completed0091100
Not completed003200
Exercise Study
Participant flow — Exercise Study
MilestoneFasted Study: Placebo/PropionateFasted Study: Propionate/PlaceboPost-Prandial Study: Placebo/PropionatePost-Prandial Study: Propionate/PlaceboExercise Study: Placebo/PropionateExercise Study: Propionate/Placebo
Started00001312
Completed0000109
Not completed000033

Outcome measures

PrimaryChanges in Resting Energy Expenditure

Changes in Resting Energy Expenditure between sodium propionate and sodium chloride (control).

Time frame:
6 hours
Reported as:
Mean · kcal/min
Changes in Resting Energy Expenditure
kcal/minPlacebo + FastingPropionate and Fasting
Changes in Resting Energy Expenditure1.013 ± 0.0341.040 ± 0.039
PrimaryChanges in Resting Lipid Oxidation

Changes in Resting Lipid Oxidation between sodium propionate and sodium chloride (control).

Time frame:
6 hours
Reported as:
Mean · g/min
Changes in Resting Lipid Oxidation
g/minPlacebo + FastingPropionate and Fasting
Changes in Resting Lipid Oxidation0.032 ± 0.0070.042 ± 0.007
PrimaryChanges in Energy Expenditure During Exercise

Changes in Energy Expenditure between sodium propionate and sodium chloride (control) during exercise.

Time frame:
240 minutes
Reported as:
Mean · kcal/min
Changes in Energy Expenditure During Exercise
kcal/minPlacebo + ExercisePropionate and Exercise
Changes in Energy Expenditure During Exercise5.085 ± 0.3304.991 ± 0.328
PrimaryChanges in Lipid Oxidation During Exercise

Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) during exercise.

Time frame:
240 minutes
Reported as:
Mean · g/min
Changes in Lipid Oxidation During Exercise
g/minPlacebo + ExercisePropionate and Exercise
Changes in Lipid Oxidation During Exercise0.284 ± 0.0320.287 ± 0.030
PrimaryChanges in Energy Expenditure Post-prandially

Changes in Energy Expenditure between sodium propionate and sodium chloride (control) post-prandially.

Time frame:
300 minutes
Reported as:
Mean · kcal/min
Changes in Energy Expenditure Post-prandially
kcal/minPlacebo + Post-prandialPropionate and Post-prandial
Changes in Energy Expenditure Post-prandially1.057 ± 0.0441.072 ± 0.046
PrimaryChanges in Lipid Oxidation Post-prandially

Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) post-prandially.

Time frame:
300 minutes
Reported as:
Mean · g/min
Changes in Lipid Oxidation Post-prandially
g/minPlacebo + Post-prandialPropionate and Post-prandial
Changes in Lipid Oxidation Post-prandially0.027 ± 0.0050.025 ± 0.005
PrimaryChanges in Glucose Concentrations Post-prandially

Changes in glucose concentrations between sodium propionate and sodium chloride (control) post-prandially.

Time frame:
300 minutes
Reported as:
Mean · mmol/L
Changes in Glucose Concentrations Post-prandially
mmol/LPlacebo + Post-prandialPropionate and Post-prandial
Changes in Glucose Concentrations Post-prandially5.38 ± 0.1335.40 ± 0.141
PrimaryChanges in Glucose Concentrations During Exercise

Changes in glucose concentrations between sodium propionate and sodium chloride (control) during exercise.

Time frame:
240 minutes
Reported as:
Mean · mmol/L
Changes in Glucose Concentrations During Exercise
mmol/LPlacebo + ExercisePropionate and Exercise
Changes in Glucose Concentrations During Exercise4.35 ± 0.094.47 ± 0.07
PrimaryChanges in Subjective Thirst Post-prandially Using a Visual Analog Scale (100 mm).

Changes in subjective thirst between sodium propionate and sodium chloride (control) post-prandially. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.

Time frame:
300 minutes
Reported as:
Mean · mm
Changes in Subjective Thirst Post-prandially Using a Visual Analog Scale (100 mm).
mmPlacebo + Post-prandialPropionate and Post-prandial
Changes in Subjective Thirst Post-prandially Using a Visual Analog Scale (100 mm).15.7 ± 4.314.5 ± 4.0
PrimaryChanges in Subjective Thirst During Exercise With Visual Analog Scales (100 mm)

Changes in subjective thirst between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.

Time frame:
240 minutes
Reported as:
Mean · mm
Changes in Subjective Thirst During Exercise With Visual Analog Scales (100 mm)
mmPlacebo + ExercisePropionate and Exercise
Changes in Subjective Thirst During Exercise With Visual Analog Scales (100 mm)39.8 ± 5.346.8 ± 5.4
PrimaryChanges in Subjective Nausea During Exercise With Visual Analog Scales (100 mm)

Changes in subjective nausea between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective nausea. High (100 mm) mean high subjective nausea.

Time frame:
240 minutes
Reported as:
Mean · mm
Changes in Subjective Nausea During Exercise With Visual Analog Scales (100 mm)
mmPlacebo + ExercisePropionate and Exercise
Changes in Subjective Nausea During Exercise With Visual Analog Scales (100 mm)2.9 ± 1.16.7 ± 3.4
PrimaryChanges in Subjective Hunger During Exercise With Visual Analog Scales (100 mm)

Changes in subjective hunger between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.

Time frame:
240 minutes
Reported as:
Mean · mm
Changes in Subjective Hunger During Exercise With Visual Analog Scales (100 mm)
mmPlacebo + ExercisePropionate and Exercise
Changes in Subjective Hunger During Exercise With Visual Analog Scales (100 mm)51.7 ± 5.757.2 ± 5.3
SecondaryChanges in GLP-1 Concentration

Changes in GLP-1 concentrations between sodium propionate and sodium chloride (control) post-prandially.

Time frame:
300 minutes
Reported as:
Mean · mmol/L
Changes in GLP-1 Concentration
mmol/LPlacebo + PostprandialPropionate and Postprandial
Changes in GLP-1 Concentration67.9 ± 7.170.5 ± 6.2
SecondaryChanges in Insulin Concentration

Changes in insulin concentrations between sodium propionate and sodium chloride (control) during fasting

Time frame:
360 minutes
Reported as:
Mean · μU/mL
Changes in Insulin Concentration
μU/mLPlacebo + FastingPropionate and Fasting
Changes in Insulin Concentration7.70 ± 0.487.87 ± 0.59
SecondaryChanges in Glucose Concentration

Changes in glucose concentrations between sodium propionate and sodium chloride (control) during fasting

Time frame:
360 minutes
Reported as:
Mean · mmol/L
Changes in Glucose Concentration
mmol/LPlacebo + FastingPropionate and Fasting
Changes in Glucose Concentration4.12 ± 0.084.14 ± 0.08
SecondaryChanges in Free Fatty Acid Concentration

Changes in free fatty acid concentrations between sodium propionate and sodium chloride (control) during fasting

Time frame:
360 minutes

No measurements were reported for this outcome.

SecondaryChanges in Subjective Nausea With Visual Analog Scales (100 mm)

Changes in subjective nausea between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective nausea. High (100 mm) mean high subjective nausea.

Time frame:
360 minutes
Reported as:
Mean · mm
Changes in Subjective Nausea With Visual Analog Scales (100 mm)
mmPlacebo + FastingPropionate and Fasting
Changes in Subjective Nausea With Visual Analog Scales (100 mm)48.0 ± 4.1144.8 ± 5.25
SecondaryChanges in Subjective Hunger With Visual Analog Scales (100 mm)

Changes in subjective hunger between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.

Time frame:
360 minutes
Reported as:
Mean · mm
Changes in Subjective Hunger With Visual Analog Scales (100 mm)
mmPlacebo + FastingPropionate and Fasting
Changes in Subjective Hunger With Visual Analog Scales (100 mm)48.0 ± 4.1144.8 ± 5.25
SecondaryChanges in Subjective Thirst Using Visual Analog Scales (100 mm)

Changes in subjective thirst between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.

Time frame:
360 minutes
Reported as:
Mean · mm
Changes in Subjective Thirst Using Visual Analog Scales (100 mm)
mmPlacebo + FastingPropionate and Fasting
Changes in Subjective Thirst Using Visual Analog Scales (100 mm)24.7 ± 5.4323.2 ± 5.25
SecondaryChanges in Insulin Concentration

Changes in insulin concentrations between sodium propionate and sodium chloride (control) during exercise

Time frame:
240 minutes
Reported as:
Mean · μU/mL
Changes in Insulin Concentration
μU/mLPlacebo + ExercisePropionate and Exercise
Changes in Insulin Concentration5.34 ± 0.395.63 ± 0.55
SecondaryChanges in Insulin Concentration

Changes in insulin concentrations between sodium propionate and sodium chloride (control) post-prandially.

Time frame:
300 minutes
Reported as:
Mean · μU/mL
Changes in Insulin Concentration
μU/mLPlacebo + Post-prandialPropionate and Postprandial
Changes in Insulin Concentration29.88 ± 2.6930.27 ± 2.17
SecondaryChanges in Subjective Nausea Between Sodium Propionate and Sodium Chloride Post-prandially

Changes in subjective nausea between sodium propionate and sodium chloride (control) post-prandially.

Time frame:
300 minutes
Reported as:
Mean · mm
Changes in Subjective Nausea Between Sodium Propionate and Sodium Chloride Post-prandially
mmPlacebo + PostprandialPropionate and Postprandial
Changes in Subjective Nausea Between Sodium Propionate and Sodium Chloride Post-prandially4.7 ± 1.85.3 ± 1.8
SecondaryChanges in Subjective Hunger Between Sodium Propionate and Sodium Chloride Post-prandially With Visual Analog Scales (100 mm)

Changes in subjective hunger between sodium propionate and sodium chloride (control) post-prandially. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.

Time frame:
300 minutes
Reported as:
Mean · mm
Changes in Subjective Hunger Between Sodium Propionate and Sodium Chloride Post-prandially With Visual Analog Scales (100 mm)
mmPlacebo + PostprandialPropionate and Postprandial
Changes in Subjective Hunger Between Sodium Propionate and Sodium Chloride Post-prandially With Visual Analog Scales (100 mm)48.8 ± 5.043.7 ± 5.4

Adverse events

Collected over 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Fasting Then Propionate and Fasting0/19 (0%)0/19 (0%)0/19 (0%)
Placebo + Exercise Then Propionate and Exercise0/19 (0%)0/19 (0%)0/19 (0%)
Placebo + Postprandial Then Propionate and Postprandial0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

Baseline analysis of 'new' participants - first assigned study.

Age, Categorical
Age, Categorical(Participants)Fasted StudyPost-prandial StudyExercise StudyTotal
<=18 years0000
Between 18 and 65 years25161253
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Fasted StudyPost-prandial StudyExercise StudyTotal
Female127423
Male139830
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Fasted StudyPost-prandial StudyExercise StudyTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(participants)Fasted StudyPost-prandial StudyExercise StudyTotal
United Kingdom25161253
BMI
BMI(kg/m^2)Fasted StudyPost-prandial StudyExercise StudyTotal
Mean23.1 ± 0.724.7 ± 0.824.5 ± 0.724.1 ± 0.7
08

Study locations

1 site
  • Imperial Clinical Research Facility
    London, W12 0HS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There is not a plan to make IPD available

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2019, 17 months.

Results were first posted in Aug 2024, 5 years after primary completion.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 17 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2019
First posted
Sep 18, 2019
StartActual
Feb 12, 2018
Primary completionActual
Aug 7, 2019
CompletionActual
Aug 7, 2019
Results first posted
Aug 23, 2024
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04093453
Responsible party
Sponsor
First posted
Sep 18, 2019
Start date
Feb 12, 2018
Primary completion
Aug 7, 2019
Completion
Aug 7, 2019
Results posted
Aug 23, 2024
Last update
Aug 23, 2024

Study contacts

Edward Chambers, PhD
study director · Imperial College London
Gary Frost, Professor
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium propionate

Start the discussion